Our study establishes hepatocyte ChREBPα as a potent anti‐fibrogenesis factor in chronic liver injury by antagonizing TGFb‐E2F1‐THBS1/CTGF signaling pathway, directly linking persistently overactive hepatocyte TGFβ signaling to liver fibrosis. Here, E2F1 is linked to Hepatic fibrosis.